Skip to main contentAI and Advanced
/
AKUMS · NSEBSE SENSEX74,314.59-0.03%BSE |
NIFTY 5023,270.6+0.23%NSE |
NIFTY BANK56,055.75-0.42%NSE |
NIFTY IT29,155.6+0.23%NSE |
NIFTY AUTO27,159.15+0.99%NSE |
NIFTY FMCG45,572.7+0.03%NSE |
NIFTY PHARMA26,579.25+1.66%NSE |
NIFTY 50022,654.65+0.54%NSE |
AK
NSE · Equity shares · Biotechnology & Drugs-5.30 · -0.69%
Akums Drugs and Pharmaceuticals AKUMS
NSE:INR 766.7
BSE:INR 765.4
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for AKUMS
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 772
Day rangeINR 763.9 — INR 789.35
52-week rangeINR 408.81 — INR 796.55
Volume2.16 L
Market cap10,385.59
P/E27.88
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)4,359.02
Net Income (INR Cr)255.19
Rev Growth (5 Year %)9.87
EPS Growth (5 Year %)16.41
P/E Ratio27.88
Book Value215.87
EPS17.55
Price/BV3.55Computed
Research path: Interpret Akums Drugs and Pharmaceuticals's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
AKUMSAkums Drugs and Pharmaceuticals1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 5,446.97 | 4,113.44 | 3,516.37 |
| Accumulated Depreciation Total | -917.81 | -783.69 | -646.97 |
| Cash Equivalents | 331.91 | 18.69 | 62.14 |
| Other Liabilities Total | 926.54 | 70.14 | 1,426.97 |
| Accrued Expenses | 69.66 | 48.35 | 48.76 |
| Common Stock Total | 30.62 | 30.62 | 28.61 |
| Other Equity Total | 0 | Not available | Not available |
| Other Current Assets Total | 4.22 | 2.24 | 6.71 |
| Prepaid Expenses | 18.84 | 16.46 | 12.71 |
| Total Assets | 5,446.97 | 4,113.44 | 3,516.37 |
| Current Portof LT Debt/Capital Leases | 80.59 | 7.23 | 51.33 |
| Additional Paid-In Capital | 1,094.18 | 1,083.97 | 127.17 |
| Cash | 54.09 | 82.5 | 48.92 |
| Total Equity | 3,313.35 | 3,047.01 | 709.5 |
| Long Term Investments | 1.27 | 3.59 | 3.79 |
| Retained Earnings(Accumulated Deficit) | 2,188.55 | 1,932.43 | 553.72 |
| Total Common Shares Outstanding | 15.31 | 15.31 | 15.74 |
| Property/Plant/Equipment Total-Gross | 2,542.73 | 2,333.49 | 2,024.2 |
| Tangible Book Valueper Share Common Eq | 215.87 | 198.34 | 44.51 |
| Goodwill Net | 2.06 | 2.06 | 2.06 |
| Total Liabilities | 2,133.62 | 1,066.43 | 2,806.87 |
| Total Debt | 157.43 | 88.21 | 565.23 |
| Short Term Investments | 1,295.05 | 480.76 | 176.77 |
| Cashand Short Term Investments | 1,681.05 | 581.95 | 287.82 |
| Total Receivables Net | 1,100.03 | 993.04 | 983.1 |
| Notes Payable/Short Term Debt | 0 | 13.66 | 367.7 |
| Deferred Income Tax | 17.71 | 18.62 | 12.15 |
| Accounts Receivable-Trade Net | 796.56 | 770.3 | 833.81 |
| Property/Plant/Equipment Total-Net | 1,624.92 | 1,549.79 | 1,377.23 |
| Minority Interest | 17.77 | 16.6 | 10.99 |
| Total Current Liabilities | 1,094.76 | 893.75 | 1,210.55 |
| Total Inventory | 755.71 | 680.93 | 650.54 |
| Accounts Payable | 602.16 | 642.79 | 532.13 |
| Other Currentliabilities Total | 342.35 | 181.73 | 210.64 |
| Total Long Term Debt | 76.84 | 67.33 | 146.2 |
| Intangibles Net | 6.21 | 8.3 | 6.89 |
| Other Long Term Assets Total | 204.67 | 243.42 | 155.98 |
| Note Receivable-Long Term | 47.97 | 31.67 | 29.54 |
| Total Current Assets | 3,559.86 | 2,274.61 | 1,940.88 |
| Capital Lease Obligations | 76.84 | 67.33 | 67.91 |
| Long Term Debt | Not available | 0 | 78.3 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.99
Price to Sale Ratio2.38
Growth
Debt 5Yr CAGR %3.64
Margins
Operating Margin 12m7.97
Operating Margin 5y Avg7.1
Net Profit Margin 12m5.88
Net Profit Margin 5y2.24
Yield
Dividend Yield %0.15
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk37.1
Analyst consensus
ConsensusStrong Buy
Consensus score1.33
Analyst opinions3
Strong Sell count0
Sell count0
Hold count0
Buy count1
Strong Buy count2
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 75.26%
- FII
- 1.91%
- MF
- 9.77%
- Other
- 13.06%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Akums Drugs & Pharmaceuticals declares dividend at 22nd AGM - scanx.tradeMarket news · 10 Jul 2026, 9:43 pm
Akums Drugs & Pharmaceuticals declares dividend at 22nd AGM scanx.trade
Akums' Maxcure Nutravedics Secures Relief from Rs 3.59 Crore Tax Penalty - Medical DialoguesMarket news · 8 Jul 2026, 7:50 pm
Akums' Maxcure Nutravedics Secures Relief from Rs 3.59 Crore Tax Penalty Medical Dialogues
Akums subsidiary penalty of INR 3.59 Cr set aside by authority - scanx.tradeMarket news · 7 Jul 2026, 12:24 am
Akums subsidiary penalty of INR 3.59 Cr set aside by authority scanx.trade
Enterprise value to revenue forward of Akums Drugs and Pharmaceuticals Limited – NSE:AKUMS - TradingViewMarket news · 6 Jul 2026, 2:56 pm
Enterprise value to revenue forward of Akums Drugs and Pharmaceuticals Limited – NSE:AKUMS TradingView
Akums launches DCGI approved triple-action therapy for diabetic peripheral neuropathic pain - Indian Pharma PostMarket news · 1 Jul 2026, 12:01 pm
Akums launches DCGI approved triple-action therapy for diabetic peripheral neuropathic pain Indian Pharma Post
Akums launches novel triple-action therapy for comprehensive neuropathy management - Express PharmaMarket news · 1 Jul 2026, 11:06 am
Akums launches novel triple-action therapy for comprehensive neuropathy management Express Pharma
Corporate actions
Events
- annual General MeetingAGM
- dividendRs.1.0000 per share(50%)Final Dividend
- dividendRs.2.0000 per share(100%)Special Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsAudited Results
Rusaka Markets Community
Discussion and sentiment for Akums Drugs and Pharmaceuticals
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Akums Drugs and Pharmaceuticals Limited is an India-based pharmaceutical contract development and manufacturing company. The Company offers a comprehensive range of pharmaceutical products and services in India and overseas. The Company’s segments include Contract Development and Manufacturing Operations (CDMO), Active Pharmaceutical Ingredient (API), Domestic Branded Formulations, International Branded Formulations, and Trade Generics. The CDMO segment is engaged in formulation research and development, preparation and regulatory filing of dossiers, manufacturing formulations on a contract basis, job work and testing services. The API segment is engaged in the manufacture and sale of key starting materials, Intermediate and API products. The Domestic Branded Formulations segment includes marketing of its branded formulations in the Indian market. The International Branded Formulations segment undertakes the marketing of its branded formulations in the global market.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- AKUMS
- BSE Code
- 544222
Questions
Stock FAQ
What is the symbol and ISIN of Akums Drugs and Pharmaceuticals?
Akums Drugs and Pharmaceuticals has the symbol AKUMS and ISIN - INE09XN01023.
What is the current price of Akums Drugs and Pharmaceuticals?
Akums Drugs and Pharmaceuticals is currently trading at INR 766.70.
What are the year high and year low of Akums Drugs and Pharmaceuticals?
Akums Drugs and Pharmaceuticals has a year high of INR 796.55 and a year low of INR 408.81.
What is the market capitalization of Akums Drugs and Pharmaceuticals?
Akums Drugs and Pharmaceuticals has a market capitalization of INR 10,385.59 crore.
What is the P/E ratio of Akums Drugs and Pharmaceuticals?
Akums Drugs and Pharmaceuticals has a P/E ratio of 27.88.
What is the dividend yield of Akums Drugs and Pharmaceuticals?
Akums Drugs and Pharmaceuticals has a dividend yield of 0.15%.
How is the financial performance of Akums Drugs and Pharmaceuticals based on revenue, net income, and EPS?
Akums Drugs and Pharmaceuticals has revenue of INR 4,359.02 crore, net income of INR 255.19 crore, and EPS of INR 17.56.
What is the book value of Akums Drugs and Pharmaceuticals?
Akums Drugs and Pharmaceuticals has a book value of INR 215.87.
What is the debt-to-equity ratio of Akums Drugs and Pharmaceuticals?
Akums Drugs and Pharmaceuticals has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Akums Drugs and Pharmaceuticals?
Akums Drugs and Pharmaceuticals has a price-to-book ratio of 3.55 and a price-to-sales ratio of 2.38.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.